LuPIN abstract, page-23

I assume Gold is referring to this statement in the last announcement:

The Company notes that one of those therapies, enzalutamide, was the subject of a US$14 billion
acquisition by Pfizer in 2016, approved for marketing in 2012 on the basis of a 5-month increase in mOS
from 13.6 to 18.4 months. Again, it is worth noting that the LuPIN outcome of 19.7 months has been
achieved in men whose cancer has already progressed on enzalutamide.

It's a little bit incorrect to conflate the valuation of enzalutamide and the basis of it's marketing approval. But, it is something to consider.